At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 11 enrolled
Drug / intervention
Placebos +4 moredrug
Likely dose
Triamcinolone Acetonide 2.5 mg/mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis
In Brief
A Phase 4 clinical trial evaluating Placebos, Triamcinolone Acetonide 2.5 mg/mL, and 3 other interventions for Nail Psoriasis and Nail Diseases. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNail Psoriasis, Nail Diseases
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartMar 2020
Primary CompletionMar 2023
TodayJul 2026
First PostedJun 19, 2019
Enrollment StartMar 11, 2020
Primary CompletionMar 29, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 7.0 years ago
Interventions
Placebosdrug
Normal saline intralesional injection
Triamcinolone Acetonide 2.5 mg/mLdrug
2.5 mg/mL intralesional injection
Triamcinolone Acetonide 5.0 mg/mLdrug
5.0 mg/mL intralesional injection
Triamcinolone Acetonide 7.5 mg/mLdrug
7.5 mg/mL intralesional injection
Triamcinolone Acetonide 10 mg/mLdrug
10 mg/mL intralesional injection